VPI 013

Drug Profile

VPI 013

Alternative Names: OPC-14523

Latest Information Update: 27 Jul 2009

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antidementias; Antidepressants; Neuroprotectants; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin uptake inhibitors; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Major depressive disorder; Neuropathic pain

Most Recent Events

  • 27 Jul 2009 No development reported - Preclinical for Neuropathic pain in USA (PO)
  • 27 Jul 2009 No development reported - Phase-II for Depression in USA (PO)
  • 25 Oct 2006 Vela Pharmaceuticals has been acquired by Pharmos Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top